Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
The dextrose component provides osmotic pressure for peritoneal dialysis, promoting ultrafiltration of fluid and removal of solutes. Calcium and other electrolytes maintain physiologic balance.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal: Continuous ambulatory peritoneal dialysis (CAPD): 2-2.5 L per exchange, 4-5 exchanges per day; Continuous cyclic peritoneal dialysis (CCPD): 2-2.5 L per exchange, 3-5 nocturnal exchanges plus one daytime dwell.
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Not applicable as a solution; glucose half-life ~20-30 min in circulation; clinical effect duration corresponds to dwell time (4-6 hours for standard exchange)
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Primarily eliminated via peritoneal dialysis; glucose is metabolized systemically and excreted as CO2 and water; <5% renal excretion of metabolites
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution